All Articles

Results of a placebo-controlled, phase 2 study (MORAb-003-011/ENGOT-ov27) indicate that the addition of farletuzumab to platinum-based chemotherapy was not superior to placebo/chemotherapy in improving progression-free survival or other efficacy parameters in patients with platinum-sensitive recurrent ovarian cancer in first relapse who had low alemtuzumab CA-125 levels.

Results of the phase 2 APPROVE trial demonstrated significant prolongation of progression-free survival with the addition of apatinib to PLD in patients with platinum-resistant or refractory recurrent ovarian cancer, with an adverse event profile consistent with that previously described for apatinib and PLD.

Final analysis of the NOVA trial supports the long-term progression-free survival benefit and safe use of niraparib beyond first progression for maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer.

Preliminary results of a phase 1 study showed favorable safety and tolerability of ribociclib, both concurrently with platinum and taxane chemotherapy and as maintenance therapy, with encouraging antitumor activity in patients with recurrent platinum-sensitive ovarian cancer

Results of the phase 3, randomized ARIEL4 trial demonstrate that patients with BRCA-mutated advanced, relapsed ovarian cancer derive significant progression-free survival benefit from rucaparib therapy compared with standard-of-care chemotherapy, with the emergence of no new safety signals.

Results of the ORZORA trial indicate that patients with platinum-sensitive relapsed ovarian cancer derived progression-free survival benefit from maintenance olaparib, irrespective of somatic or germline BRCA mutation status.

Secondary efficacy data and subgroup analyses from the LIGHT study indicate that olaparib monotherapy was most effective in BRCA-mutated cohorts of patients with platinum-sensitive relapsed ovarian cancer.

Five-year follow-up results of the SOLO1 trial indicate that 2 years of maintenance olaparib provides sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer harboring BRCA1 and/or BRCA2 mutations, with no emergence of new safety signals.

Results of the subgroup analysis of the ARIEL4 study suggest that heavily pretreated patients with advanced relapsed ovarian carcinoma harboring a BRCA1/2 mutation derive progression-free survival benefit from rucaparib treatment across all platinum-sensitivity subgroups.

Results of the PAOLA-1/ENGOT-ov25 study demonstrated sustained progression-free survival benefit with the addition of maintenance olaparib to bevacizumab, compared with placebo and bevacizumab in homologous recombination deficiency-positive patients, irrespective of International Federation of Gynecology and Obstetrics stage and residual disease after up-front surgery.